Using aspirin to prevent preeclampsia in women after assisted reproductive technology

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to determine if aspirin can effectively prevent preeclampsia and improve pregnancy outcomes in nulliparous women who conceive through assisted reproductive technology (ART). It focuses on women who are at high risk for preeclampsia and examines the efficacy of aspirin prophylaxis when administered during early pregnancy. The study will compare outcomes between those receiving aspirin and those receiving a placebo, with a particular emphasis on identifying high-risk patients who could benefit from this treatment. The research is set in France, where current guidelines restrict aspirin use to women with specific risk factors, potentially overlooking others who may also benefit.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Nulliparous women aged 18 years or more
* Pregnancy following ART, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), oocyte donation or intrauterine insemination with sperm donor
* Singleton pregnancy
* Evolutive pregnancy between 9 and 14 weeks of gestation
* Women affiliated to a French Social Security Insurance or equivalent social protection
* Written informed consent

Exclusion Criteria:

* Major fetal abnormality
* Regular treatment with aspirin (including antiphospholipid syndrome)
* Aspirin contraindications (allergy, von Willebrand disease, peptic ulceration, hemophilia)
* Women protected by law.
* Women included in another interventional study.

Where it's running

• CHU Angers
  Angers, France Recruiting
• CHU Bordeaux
  Bordeaux, France Recruiting
• CHU Clermont-Ferrand
  Clermont-Ferrand, France Recruiting
• CHU Dijon-Bourgogne
  Dijon, France Recruiting
• CHU Lille
  Lille, France Recruiting
• HCL - Groupement Hospitalier Est, Hôpital Femme Mère Enfant
  Lyon, France Recruiting

Study contacts

• Principal investigator: Christophe VAYSSIERE, MD — University Hospital, Toulouse
• Study coordinator: Paul GUERBY, MD
• Email: guerby.p@chu-toulouse.fr
• Phone: 5 67 77 12 33

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pre-eclampsia risk in pregnancies after oocyte donation

  We will follow pregnant women who used donated eggs and women who used their own eggs to see if pregnancies after oocyte donation lead to a higher risk of pre-eclampsia.

  Recruiting at 6 sites Copenhagen University Hospital, Hvidovre · Copenhagen and 5 other locations · NCT07263490

• Use of metformin to prolong pregnancy in preterm preeclampsia in the Netherlands

  In pregnant people with preterm preeclampsia, this study tests whether metformin can help them stay pregnant longer compared with placebo.

  Recruiting Phase 3 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT06452498

• Preeclampsia Biomarker Test in African Women

  This study tests whether measuring the sFlt-1/PlGF ratio using quick clinic tests helps predict which pregnant women in Africa will develop severe preeclampsia.

  Recruiting Africa Clinical Research Network (ACRN) · Harare, Harare · NCT07810439

• Internal jugular vein collapsibility to gauge volume status in preeclampsia vs. normal pregnancy

  This study tests whether ultrasound of the internal jugular vein can show differences in fluid status between preeclamptic pregnant people and those with normal blood pressure during planned cesarean delivery.

  Recruiting Tanta University · Tanta, El-Gharbia Govenorate · NCT07786246

• Blood pressure checker Withings BPM Pro 2 in pregnancy

  This study tests whether the Withings BPM Pro 2 blood pressure monitor gives accurate readings for pregnant people, including those with high blood pressure or preeclampsia.

  Recruiting Withings · Yerevan, Armenia · NCT07595016

• How the placenta affects maternal and fetal health

  This project will test whether tiny particles released by the placenta differ in pregnancies with pre-eclampsia, gestational diabetes, or fetal growth restriction compared with healthy pregnancies and non-pregnant women.

  Recruiting University of Oxford · Oxford · NCT07470320

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.